Ireland drug approval row over Skyclarys
Analysis based on 9 articles · First reported Jul 16, 2026 · Last updated Jul 16, 2026
The dispute may delay market access for Skyclarys in Ireland, affecting the manufacturer's revenue. However, the impact is limited as Ireland is a small market; the broader review of drug assessment could influence future pharmaceutical pricing and reimbursement.
A political dispute has erupted in Ireland over the slow approval process for the drug Skyclarys, used to treat Friedreich's Ataxia. Opposition leader Mary Lou McDonald raised the issue in the Dail, criticizing delays after the HSE Drugs Group referred the drug to an expert committee instead of recommending reimbursement. Taoiseach Simon Harris defended the process, noting mixed scientific views and a four-week deadline for the committee. Tanaiste and Minister for Health Jennifer Carroll MacNeill committed to a review of the medicines assessment system. Skyclarys is approved in several EU countries, the UK, Canada, and the US.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard